Summary of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings

May 17, 2018 - By Sarah Holford

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Corporate Logo

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

A total of 2 analysts rate HTG Molecular Diagnostics (NASDAQ:HTGM) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:HTGM) has 10 ratings reports on May 17, 2018 according to StockzIntelligence. On Friday, March 23 H.C. Wainwright maintained the shares of HTGM in report with “Buy” rating. On Friday, March 23 the company was maintained by Canaccord Genuity. On Monday, January 8 the rating was maintained by Canaccord Genuity with “Buy”. On Friday, January 5 the stock has “Buy” rating by Canaccord Genuity. In Tuesday, May 8 report H.C. Wainwright maintained it with “Buy” rating and $700 target. The company rating was maintained by H.C. Wainwright on Wednesday, January 24. On Thursday, February 1 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, April 17 the firm has “Buy” rating given by H.C. Wainwright. On Friday, January 5 H.C. Wainwright maintained the shares of HTGM in report with “Buy” rating. On Wednesday, December 27 the stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has “Buy” rating given by H.C. Wainwright. Listed here are HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) PTs and latest ratings.

08/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
17/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
23/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $7 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

The stock decreased 3.56% or $0.13 during the last trading session, touching $3.52.Currently HTG Molecular Diagnostics, Inc. is downtrending after 59.58% change in last May 17, 2017. HTGM has also 207,215 shares volume. The stock underperformed the S&P500 by 71.13%.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling.The company has $99.81 million market cap. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.Currently it has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

For more HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news announced recently go to: Nasdaq.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the …” announced on May 10, 2018, “HTG Molecular Diagnostics Reports First Quarter 2018 Results” on May 10, 2018, “HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10” with a publish date: April 27, 2018, “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” and the last “HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic …” with publication date: May 07, 2018.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.